TH-302 (BioDeep_00000771861)
代谢物信息卡片
化学式: C9H16Br2N5O4P (446.9306586000001)
中文名称: 艾伏磷酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
InChI: InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
描述信息
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10704
- PubChem: 11984561
- DrugBank: DB06091
- ChEMBL: CHEMBL260046
- CAS: 918633-87-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Nguyen H Tran, Nathan R Foster, Amit Mahipal, Thomas Byrne, Joleen Hubbard, Alvin Silva, Kabir Mody, Steven Alberts, Mitesh J Borad. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
Investigational new drugs.
2021 08; 39(4):1072-1080. doi:
10.1007/s10637-021-01090-w. [PMID: 33646489] - Linda Spiegelberg, Stefan J van Hoof, Rianne Biemans, Natasja G Lieuwes, Damiënne Marcus, Raymon Niemans, Jan Theys, Ala Yaromina, Philippe Lambin, Frank Verhaegen, Ludwig J Dubois. Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
2019 12; 141(?):247-255. doi:
10.1016/j.radonc.2019.06.034. [PMID: 31431383] - Cho Rong Hong, William R Wilson, Kevin O Hicks. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Neoplasia (New York, N.Y.).
2019 02; 21(2):159-171. doi:
10.1016/j.neo.2018.11.009. [PMID: 30591421] - Donald Jung, Hailong Jiao, Jian-Xi Duan, Mark Matteucci, Ronghua Wang. Metabolism and excretion of TH-302 in dogs.
Xenobiotica; the fate of foreign compounds in biological systems.
2012 Jul; 42(7):687-700. doi:
10.3109/00498254.2011.650234. [PMID: 22352389] - Donald Jung, Hailong Jiao, Jian-Xi Duan, Mark Matteucci, Ronghua Wang. Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2012 Apr; 42(4):372-88. doi:
10.3109/00498254.2011.622810. [PMID: 22004352] - Donald Jung, Lin Lin, Hailong Jiao, Xiaohong Cai, Jian-Xin Duan, M Matteucci. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Cancer chemotherapy and pharmacology.
2012 Mar; 69(3):643-54. doi:
10.1007/s00280-011-1741-6. [PMID: 21964906] - Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, Mitesh J Borad, Johanna C Bendell, Julian R Molina, Raoul Tibes, Ramesh K Ramanathan, Karen Lewandowski, Suzanne F Jones, Mario E Lacouture, Virginia K Langmuir, Hank Lee, Stew Kroll, Howard A Burris. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011 May; 17(9):2997-3004. doi:
10.1158/1078-0432.ccr-10-3425. [PMID: 21415214]